Clinical trials: Alcoholic Liver Disease
Liver Diseases
Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)
The purpose of this study is to determine if therapy with pioglitazone or vitamin E will lead to an improvement in liver histology in non-diabetic adult patients with non-alcoholic steatohepatitis (NASH).
- Trial name
- PIVENS (NCT00063622)
- Testing
- Pioglitazone, Vitamin E
- Where
- 8 sites in United States
- Volunteers
- 247 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Nonalcoholic Fatty Liver Disease
Effect of Mediterranean Diet in Obese Adolescents With Nonalcoholic Fatty Liver Disease
The aim of this study was to evaluate the effects of mediterranean and low-fat diet on hepatic fat, inflammation markers and oxidative stress in adolescents with nonalcoholic fatty liver disease.
- Trial name
- NCT04845373
- Testing
- Mediterranean diet, Control diet: Low fat diet
- Where
- Turkey (Türkiye)
- Volunteers
- 44 people
- Sponsor
- Gazi University
NAFLD, Accupuncture
Treatment of Non Alcoholic Fatty Liver Disease With Lifestyle Modification and Acupuncture
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver dysfunction worldwide. NAFLD may progress to nonalcoholic steatohepatitis (NASH) and in turn to cirrhosis.
- Trial name
- NCT02006329
- Testing
- acupuncture
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Ziv Hospital
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis With Liver Fibrosis
Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)
The study aims to evaluate two, orally administered, investigational agents - PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor).
- Trial name
- MIRNA (NCT04321031)
- Testing
- PF-06865571, PF-05221304
- Where
- 291 sites in United States, Bulgaria and 10 more
- Volunteers
- 256 people
- Sponsor
- Pfizer
Fatty Liver, Intermittent Fasting
Intermittent Fasting for NAFLD in Adults
NAFLD is a growing threat to public health. Currently, there is a significant need for highly effective treatments for NAFLD. Non-obese NAFLD (BMI<30kg/m2) is an increasingly recognized condition, sometimes described as "lean…
- Conditions
- Fatty Liver, Intermittent Fasting, Fatty Liver, Nonalcoholic, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT04899102
- Testing
- Time-Restricted, Intermittent Fasting
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Massachusetts General Hospital
Obesity, Diabetes
Role of Dietary Fatty Acids in Fatty Liver and Insulin Resistance
The purpose of this study is to investigate whether substituting saturated fats with polyunsaturated fats reduces fatty liver and improves insulin action and other metabolic variables in abdominally obese subjects
- Conditions
- Obesity, Diabetes, Insulin Resistance, Fatty Liver
- Trial name
- HEPFAT (NCT01038102)
- Testing
- PUFA Diet, SFA diet
- Where
- Sweden
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Uppsala University
Non-Alcoholic Fatty Liver Disease, Hyperuricemia
Assocaiton Between Uric Acid Trajecteries and Remission of NAFLD in NAFLD Individuals
Uric acid is the end product of dietary or endogenous purines degradation, and hyperuricemia is one of the most common metabolic disorders.
- Trial name
- NCT05245890
- Volunteers
- 2,000 people
- Sponsor
- Ningbo No. 1 Hospital
Nonalcoholic Steatohepatitis
Using Hydroxychloroquine to Treat Nonalcoholic Steatohepatitis
Nonalcoholic steatohepatitis (NASH) is a serious type of nonalcoholic fatty liver disease (NAFLD), which is characterized by lobular inflammation and apoptosis resulting from hepatic steatosis in the absence of excessive alcohol…
- Trial name
- NCT05733897
- Testing
- hydroxychloroquine
- Where
- 2 sites in Taiwan
- Volunteers
- 150 people
- Sponsor
- National Taiwan University Hospital
Coronary Disease, Non-alcoholic Fatty Liver Disease
Non-invasive Liver Screening for Risk Assessment for Coronary Heart Disease
Background: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome, which is one of the major risk factors of coronary heart disease (CHD).
- Conditions
- Coronary Disease, Non-alcoholic Fatty Liver Disease, Elasticity Imaging Techniques
- Trial name
- NILS-R-CHD (NCT02779946)
- Testing
- Fibro Scan, PNPLA3
- Where
- Germany
- Volunteers
- 216 people
- Sponsor
- University of Leipzig
Non-Alcoholic Fatty Liver Disease
Hepatic Urea Nitrogen Handling in Patients With NASH
The aim of the project is to investigate the metabolic regulation of the hepatic urea nitrogen handling and various cognitive functions measured by psychometric and neurophysiological tests before and after bariatric surgery in…
- Trial name
- NCT03260036
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- University of Aarhus
Nonalcoholic Steatohepatitis
Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can cause fibrosis regression and reduce progression to cirrhosis and associated complications in adults with NASH and bridging (F3) fibrosis.
- Trial name
- STELLAR-3 (NCT03053050)
- Testing
- SEL
- Where
- 298 sites in United States, Argentina and 25 more
- Volunteers
- 808 people
- Sponsor
- Gilead Sciences
Liver Disease, Alcoholic
Effects of SAMe in Patients With Alcoholic Liver Disease
Prior studies in animal models have established that the pathogenesis of alcoholic liver disease (ALD) is regulated in part by the effects of chronic alcohol abuse on hepatic methionine metabolism.
- Trial name
- NCT00573313
- Testing
- S-adenosylmethionine
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Alcoholic Hepatitis
Pegfilgrastim in Patients With Alcoholic Hepatitis
This is a multi-center, prospective, randomized trial of standard of care vs. standard of care + pegfilgrastim (Neulasta®) among patients with a clinical diagnosis of alcoholic hepatitis and DF≥32.
- Trial name
- NCT02776059
- Testing
- Standard of care + pegfiltrastim, Standard of care
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Timothy Morgan, MD
Obesity Prevention, Pediatric Obesity
Relationship Between Eating Patterns, Body Composition and the Detection of Fatty Liver in Children and Adolescents With Trisomy 21: LiverTy Project
Childhood obesity is a growing public health issue affecting millions of children worldwide, increasing the risk of metabolic and cardiovascular diseases in adulthood.
- Conditions
- Obesity Prevention, Pediatric Obesity, Trisomy 21, Down Syndrome (Trisomy 21)
- Trial name
- LiverTy (NCT06888570)
- Testing
- To evaluate fat liver content in the cases/controls population.
- Where
- Spain
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- IMDEA Food
Nonalcoholic Fatty Liver Disease (NAFLD)
Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD
The purpose of this research is to gather information on the combination Zetia® (Ezetimibe) and Urso Forte® with respect to sterol balance and their effects on biomarkers of liver function in subjects with nonalcoholic fatty…
- Trial name
- NCT02244944
- Testing
- EZ-Urso combination therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Gregory Graf, PhD
Diabetes Mellitus, Non-alcoholic Fatty Liver Disease
Transplantation of Microbes for Treatment of Metabolic Syndrome & NAFLD
Non-alcoholic fatty liver disease (NAFLD) occurs when excess fat is deposited in the liver. Almost all patients also have obesity and insulin resistance (the inability of the body to effectively use insulin).
- Trial name
- FMT (NCT02496390)
- Testing
- Autologous, Allogeneic
- Where
- Canada
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Obese Patients With Non-alcoholic Steatohepatitis (NASH)
Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients
The purpose of this study was to assess the effects of LIK066 on a variety of metabolic and inflammation biomarkers in patients with non-alcoholic steatohepatitis (NASH)
- Trial name
- NCT03205150
- Testing
- LIK066
- Where
- 15 sites in United States, Argentina and 6 more
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
Non-alcoholic Fatty Liver Disease
the Role of plin5 in the Development of Nonalcoholic Fatty Liver Disease.
To further clarify the role of sequence polymorphism in patatin-like phospholipid domain containing protein 3 in the development of nonalcoholic fatty liver disease.
- Trial name
- NCT04104282
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Xijing Hospital
Obesity, NAFLD
Low-Calorie Diet in People With Prediabetes/Metabolic Syndrome
Significant weight reduction, achieved by low-calorie diet (LCD), will mobilise ectopic fat (visceral and particularly liver fat), improving insulin sensitivity and other metabolic syndrome components, with secondary beneficial…
- Conditions
- Obesity, NAFLD, Fatty Liver, Pre Diabetes
- Trial name
- CALIBRATE (NCT04786418)
- Testing
- Standard of care, Low-calorie diet
- Where
- United Kingdom
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of Liverpool
Nonalcoholic Steatohepatitis
A Study to See if Low Level Laser Light Therapy (LLLT) Can Improve the Condition of Nonalcoholic Steatohepatitis (NASH)
The purpose of this study is to determine whether low level laser therapy (LLLT) using the Erchonia VERJU and EVRL laser devices is effective in reducing aminoalanine transaminase (ALT) levels in individuals with nonalcoholic…
- Trial name
- NCT03163810
- Testing
- Erchonia Verju Laser, Erchonia EVRL Laser
- Where
- United States
- Sponsor
- Erchonia Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.